STOCK TITAN

[144] Bio-Techne Corp. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Form 144 notice for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $957,849.07. The filing shows the shares outstanding are 155,549,587 and lists the approximate sale date as 08/25/2025 on NASDAQ. The securities were acquired on 08/25/2025 by exercise of options under a registered plan from the issuer and payment is shown as cash. The filer represents they are not aware of undisclosed material adverse information. Several identifying fields such as the filer name/CIK and issuer address are not provided in the text.

Avviso Form 144 per Bio-Techne Corp. (TECH) segnala una proposta di vendita di 17.040 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato complessivo di $957.849,07. Il deposito indica che le azioni in circolazione sono 155.549.587 e riporta la data approssimativa di vendita come 25/08/2025 su NASDAQ. I titoli sono stati acquisiti il 25/08/2025 mediante l’esercizio di opzioni nell’ambito di un piano registrato dall’emittente e il pagamento risulta effettuato in contanti. Il dichiarante afferma di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate. Diversi campi identificativi, come il nome del dichiarante/CIK e l’indirizzo dell’emittente, non sono forniti nel testo.

Aviso Form 144 para Bio-Techne Corp. (TECH) informa sobre una propuesta de venta de 17.040 acciones ordinarias a través de Morgan Stanley Smith Barney con un valor de mercado agregado de $957.849,07. La presentación muestra que las acciones en circulación son 155.549.587 y señala la fecha aproximada de venta como 25/08/2025 en NASDAQ. Los valores se adquirieron el 25/08/2025 mediante el ejercicio de opciones bajo un plan registrado por el emisor y el pago figura como efectivo. El declarante manifiesta no tener conocimiento de información adversa material no divulgada. Varios campos identificativos, como el nombre del declarante/CIK y la dirección del emisor, no aparecen en el texto.

Bio-Techne Corp. (TECH) 관련 Form 144 공지에는 Morgan Stanley Smith Barney를 통해 보통주 17,040주를 총시가 $957,849.07에 매각하려는 제안이 보고되어 있습니다. 제출서에는 발행 주식수가 155,549,587주이며, NASDAQ에서의 대략적인 매각일은 2025-08-25로 기재되어 있습니다. 해당 증권은 2025-08-25에 발행사의 등록된 계획에 따른 옵션 행사로 취득되었고, 지급 수단은 현금으로 표시되어 있습니다. 제출인은 공개되지 않은 중요한 불리한 정보를 알고 있지 않다고 진술하고 있습니다. 제출인 이름/CIK 및 발행사 주소 등 여러 식별 항목은 본문에 제공되지 않았습니다.

Avis Form 144 pour Bio-Techne Corp. (TECH) signale une proposition de vente de 17 040 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande globale de 957 849,07 $. Le dépôt indique que le nombre d'actions en circulation est de 155 549 587 et mentionne la date approximative de vente comme le 25/08/2025 sur le NASDAQ. Les titres ont été acquis le 25/08/2025 par exercice d'options dans le cadre d'un plan enregistré par l'émetteur et le paiement est indiqué en espèces. Le déclarant affirme ne pas avoir connaissance d'informations défavorables importantes non divulguées. Plusieurs champs d'identification, tels que le nom du déclarant/CIK et l'adresse de l'émetteur, ne sont pas fournis dans le texte.

Form 144-Mitteilung für Bio-Techne Corp. (TECH) meldet einen geplanten Verkauf von 17.040 Stammaktien über Morgan Stanley Smith Barney mit einem Gesamtmarktwert von $957.849,07. Die Einreichung gibt an, dass die ausstehenden Aktien 155.549.587 betragen und nennt das ungefähre Verkaufsdatum als 25.08.2025 an der NASDAQ. Die Wertpapiere wurden am 25.08.2025 durch Ausübung von Optionen im Rahmen eines beim Emittenten registrierten Plans erworben, und die Zahlung wird als Bargeld angegeben. Der Melder erklärt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu kennen. Mehrere identifizierende Felder, wie der Name des Melders/CIK und die Adresse des Emittenten, sind im Text nicht enthalten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider sale notice for 17,040 shares; size is immaterial relative to outstanding shares.

This Form 144 documents a proposed sale following an option exercise and cash payment. The aggregate value (~$958k) represents a small fraction of the issuer's reported outstanding shares (155.5 million), indicating the transaction is unlikely to materially affect capital structure or market liquidity. The filing contains basic sale mechanics and broker details but omits the filer identity in the provided text, which limits assessment of insider status or potential signaling.

TL;DR: Filing meets Rule 144 mechanics but missing some identifying details in the provided extract.

The notice shows acquisition by exercise under a registered plan and planned resale through a broker on a single date with cash payment, consistent with standard Rule 144 disclosures. The signature/representation language about lack of undisclosed material information is present. However, the excerpt lacks explicit filer and issuer contact details, which are typically included on a complete Form 144; that omission in the supplied content prevents full compliance verification from this extract alone.

Avviso Form 144 per Bio-Techne Corp. (TECH) segnala una proposta di vendita di 17.040 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato complessivo di $957.849,07. Il deposito indica che le azioni in circolazione sono 155.549.587 e riporta la data approssimativa di vendita come 25/08/2025 su NASDAQ. I titoli sono stati acquisiti il 25/08/2025 mediante l’esercizio di opzioni nell’ambito di un piano registrato dall’emittente e il pagamento risulta effettuato in contanti. Il dichiarante afferma di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate. Diversi campi identificativi, come il nome del dichiarante/CIK e l’indirizzo dell’emittente, non sono forniti nel testo.

Aviso Form 144 para Bio-Techne Corp. (TECH) informa sobre una propuesta de venta de 17.040 acciones ordinarias a través de Morgan Stanley Smith Barney con un valor de mercado agregado de $957.849,07. La presentación muestra que las acciones en circulación son 155.549.587 y señala la fecha aproximada de venta como 25/08/2025 en NASDAQ. Los valores se adquirieron el 25/08/2025 mediante el ejercicio de opciones bajo un plan registrado por el emisor y el pago figura como efectivo. El declarante manifiesta no tener conocimiento de información adversa material no divulgada. Varios campos identificativos, como el nombre del declarante/CIK y la dirección del emisor, no aparecen en el texto.

Bio-Techne Corp. (TECH) 관련 Form 144 공지에는 Morgan Stanley Smith Barney를 통해 보통주 17,040주를 총시가 $957,849.07에 매각하려는 제안이 보고되어 있습니다. 제출서에는 발행 주식수가 155,549,587주이며, NASDAQ에서의 대략적인 매각일은 2025-08-25로 기재되어 있습니다. 해당 증권은 2025-08-25에 발행사의 등록된 계획에 따른 옵션 행사로 취득되었고, 지급 수단은 현금으로 표시되어 있습니다. 제출인은 공개되지 않은 중요한 불리한 정보를 알고 있지 않다고 진술하고 있습니다. 제출인 이름/CIK 및 발행사 주소 등 여러 식별 항목은 본문에 제공되지 않았습니다.

Avis Form 144 pour Bio-Techne Corp. (TECH) signale une proposition de vente de 17 040 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande globale de 957 849,07 $. Le dépôt indique que le nombre d'actions en circulation est de 155 549 587 et mentionne la date approximative de vente comme le 25/08/2025 sur le NASDAQ. Les titres ont été acquis le 25/08/2025 par exercice d'options dans le cadre d'un plan enregistré par l'émetteur et le paiement est indiqué en espèces. Le déclarant affirme ne pas avoir connaissance d'informations défavorables importantes non divulguées. Plusieurs champs d'identification, tels que le nom du déclarant/CIK et l'adresse de l'émetteur, ne sont pas fournis dans le texte.

Form 144-Mitteilung für Bio-Techne Corp. (TECH) meldet einen geplanten Verkauf von 17.040 Stammaktien über Morgan Stanley Smith Barney mit einem Gesamtmarktwert von $957.849,07. Die Einreichung gibt an, dass die ausstehenden Aktien 155.549.587 betragen und nennt das ungefähre Verkaufsdatum als 25.08.2025 an der NASDAQ. Die Wertpapiere wurden am 25.08.2025 durch Ausübung von Optionen im Rahmen eines beim Emittenten registrierten Plans erworben, und die Zahlung wird als Bargeld angegeben. Der Melder erklärt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu kennen. Mehrere identifizierende Felder, wie der Name des Melders/CIK und die Adresse des Emittenten, sind im Text nicht enthalten.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Bio-Techne (TECH) report?

It reports a proposed sale of 17,040 common shares through Morgan Stanley Smith Barney with aggregate market value of $957,849.07 and an approximate sale date of 08/25/2025.

How were the shares acquired according to the filing?

The shares were acquired on 08/25/2025 by exercise of options under a registered plan from the issuer, with payment made in cash.

Does the filing identify the broker and exchange?

Yes. The broker is Morgan Stanley Smith Barney LLC and the securities are listed for sale on NASDAQ.

Is the filer identified in the provided content?

No. The supplied extract does not include the filer name or CIK, so the filer’s identity cannot be confirmed from this text.

Does the filing disclose other sales in the past three months?

No. The section for securities sold during the past three months states "Nothing to Report".
Bio-Techne Corp

NASDAQ:TECH

TECH Rankings

TECH Latest News

TECH Latest SEC Filings

TECH Stock Data

9.33B
155.28M
1.1%
103.38%
3.29%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS